W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

Transparency Council

Summary of information indicated by applicants to be kept confidential in selected areas of the documentation published by AOTMiT (applicant’s analyses, verification analyses, positions of the Transparency Council, recommendations of the President) in the evaluation of reimbursement applications for the year 2021 and Q1 2022.

more...

The Meeting of the Transparency Council No. 32/2022 of 16.08.2022

more...

The Meeting of the Transparency Council No. 31/2022 of 11.08.2022

more...

The Meeting of the Transparency Council No. 30/2022 of 01.08.2022.

more...

Opinion of the Transparency Council – health policy programme on therapeutic rehabilitation (town of Żyrardów)

more...

Opinion of the Transparency Council – health policy programme on breast cancer prevention (town of Sieradz)

more...

Opinion of the Transparency Council – changes to the drug programme B.61

more...

Opinion of the Transparency Council – active substance ipratropii bromidum

more...

Opinion of the Transparency Council – active substances fenoteroli hydrobromidum + ipratropii bromidum

more...

Opinion of the Transparency Council – active substance prednisone

more...

Opinion of the Transparency Council – active substances amiloridum + hydrochlorothiazidum

more...

Opinion of the Transparency Council – health policy programme on medical rehabilitation (Municipality of Mielno)

more...

Opinion of the Transparency Council – health policy programme on detection of vision defects (Municipality of Chociwel)

more...

Opinion of the Transparency Council – health policy programme on detection of vision defects (town of Będzin)

more...

Position of the Transparency Council – Rezurock (belumosudil)

more...

Position of the Transparency Council – Yervoy (ipilimumab)

more...

Position of the Transparency Council – Opdivo (nivolumab)

more...

Opinion of the Transparency Council – combining drug programmes B.29 and B.46

more...

Position of the Transparency Council – non gamma 2 capsule amalgam

more...

The Meeting of the Transparency Council No. 29/2022 of 25.07.2022

more...

Opinion of the Transparency Council – leflunomidum

more...

Position of the Transparency Council – Livmarli (maralixibat)

more...

Opinion of the Transparency Council – health policy programme of the Municipality of Kołobrzeg in the scope of prevention of overweight and obesity in children

more...

The Meeting of the Transparency Council No. 28/2022 of 18.07.2022

more...